Variant	Variant_b37	GeneSymbol.x	VariationID	AlleleID	Type	LastEvaluated	NumberSubmitters	chr	pos	REF	ALT	last_evaluated	n_called	n_not_called	AC	n_het	flag_HC_lab_unspecified_phenotype	high_confidence_lab_2017_any	high_confidence_lab_2017_clinical_significance	variant_str	assessment1	assessment1_notes	assessment2	assessment2_notes	assessment3	assessment3_notes	Curated_Phenotype	Level	Notes	Traitschr2-21006288-C-T	2-21229160-C-T	APOB	17890	32929	single nucleotide variant	11-Jul-18	18	chr2	21006288	C	T	7/11/18	49960	0	37	37	FALSE	TRUE	"Pathogenic, Pathogenic, Pathogenic"	chr2:21006288:C:T	NA	NA	NA	NA	Pathogenic	"Relatively high frequency, but hypercholesterolemia has reduced prevalence and other evidence is very convincing"	"hypercholesterolemia, autosomal dominant, type b (High LDL)"	Pathogenic	"Relatively high frequency, but hypercholesterolemia has reduced prevalence and other evidence is very convincing"	High LDLchr2-21006289-G-A	2-21229161-G-A	APOB	40223	48709	single nucleotide variant	3-Jul-18	8	chr2	21006289	G	A	7/3/18	49960	0	3	3	FALSE	FALSE	"Pathogenic, Pathogenic, Pathogenic"	chr2:21006289:G:A	NA	NA	NA	NA	Pathogenic	"High frequency, likely due to fact that it can have recessive inheritence for low LDL"	"hypercholesterolemia, autosomal dominant, type b (high LDL)"	Pathogenic	"High frequency, likely due to fact that it can have recessive inheritence for low LDL"	High LDLchr19-11120082-G-T	19-11230758-G-T	LDLR	252072	246373	single nucleotide variant	29-Aug-17	3	chr19	11120082	G	T	8/29/17	49960	0	3	3	TRUE	FALSE	NA	chr19:11120082:G:T	NA	NA	Likely Benign	NA	NA	NA	NA	Likely Benign	NA	High LDLchr19-11111620-G-A	19-11222296-G-A	LDLR	256365	256754	single nucleotide variant	30-Mar-17	2	chr19	11111620	G	A	3/30/17	49960	0	12	12	FALSE	FALSE	NA	chr19:11111620:G:A	NA	NA	vus	NA	NA	NA	NA	vus	NA	High LDLchr19-11100320-C-G	19-11210996-C-G	LDLR	369857	354078	single nucleotide variant	NA	2	chr19	11100320	C	G	NA	49960	0	2	2	FALSE	FALSE	NA	chr19:11100320:C:G	NA	NA	Likely Benign	NA	NA	NA	NA	Likely Benign	NA	High LDLchr19-11113743-G-A	19-11224419-G-A	LDLR	3696	18735	single nucleotide variant	30-Mar-17	13	chr19	11113743	G	A	3/30/17	49960	0	1	1	FALSE	FALSE	NA	chr19:11113743:G:A	NA	NA	NA	NA	Likely Pathogenic	NA	familial hypercholesterolemia (high LDL)	Likely Pathogenic	NA	High LDLchr19-11102785-TCG-T	19-11213461-TCG-T	LDLR	226316	228129	deletion	30-Mar-17	5	chr19	11102785	TCG	T	3/30/17	49958	2	1	1	FALSE	FALSE	NA	chr19:11102785:TCG:T	NA	NA	NA	NA	Likely Pathogenic	NA	familial hypercholesterolemia	Likely Pathogenic	NA	High LDLchr19-11107486-C-G	19-11218162-C-G	LDLR	226336	228149	single nucleotide variant	2-Jan-18	6	chr19	11107486	C	G	1/2/18	49960	0	1	1	FALSE	FALSE	NA	chr19:11107486:C:G	NA	NA	NA	NA	Likely Pathogenic	NA	familial hypercholesterolemia	Likely Pathogenic	NA	High LDLchr19-11111522-G-A	19-11222198-G-A	LDLR	251649	245971	single nucleotide variant	30-Mar-17	5	chr19	11111522	G	A	3/30/17	49960	0	1	1	FALSE	FALSE	NA	chr19:11111522:G:A	NA	NA	NA	NA	Likely Pathogenic	NA	familial hypercholesterolemia	Likely Pathogenic	NA	High LDLchr19-11116141-G-A	19-11226817-G-A	LDLR	251945	246250	single nucleotide variant	31-Oct-18	3	chr19	11116141	G	A	10/31/18	49960	0	3	3	FALSE	FALSE	NA	chr19:11116141:G:A	NA	NA	NA	NA	Likely Pathogenic	"Might have used PM2_supporting, but would still be LP"	familial hypercholesterolemia (high LDL)	Likely Pathogenic	"Might have used PM2_supporting, but would still be LP"	High LDLchr19-11120419-T-A	19-11231095-T-A	LDLR	252183	246478	single nucleotide variant	16-Dec-16	2	chr19	11120419	T	A	12/16/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11120419:T:A	NA	NA	NA	NA	Likely Pathogenic	NA	familial hypercholesterolemia	Likely Pathogenic	NA	High LDLchr19-11106588-G-A	19-11217264-G-A	LDLR	200920	198013	single nucleotide variant	22-May-18	9	chr19	11106588	G	A	5/22/18	49960	0	2	2	FALSE	FALSE	NA	chr19:11106588:G:A	NA	NA	Likely Pathogenic	NA	VUS	NA	NA	VUS	NA	High LDLchr19-11120144-G-A	19-11230820-G-A	LDLR	226380	228193	single nucleotide variant	28-Nov-17	7	chr19	11120144	G	A	11/28/17	49960	0	1	1	FALSE	FALSE	NA	chr19:11120144:G:A	NA	NA	Likely Pathogenic	NA	VUS	NA	NA	VUS	NA	High LDLchr19-11113308-G-A	19-11223984-G-A	LDLR	228798	230981	single nucleotide variant	30-Mar-17	6	chr19	11113308	G	A	3/30/17	49960	0	1	1	FALSE	FALSE	NA	chr19:11113308:G:A	NA	NA	Likely Pathogenic	NA	VUS	NA	NA	VUS	NA	High LDLchr19-11113705-C-T	19-11224381-C-T	LDLR	251886	246200	single nucleotide variant	5-Nov-16	2	chr19	11113705	C	T	11/5/16	49960	0	2	2	FALSE	FALSE	NA	chr19:11113705:C:T	NA	NA	Likely Pathogenic	NA	VUS	NA	NA	VUS	NA	High LDLchr19-11113620-G-A	19-11224296-G-A	LDLR	161284	171214	single nucleotide variant	11-May-17	13	chr19	11113620	G	A	5/11/17	49960	0	5	5	FALSE	FALSE	NA	chr19:11113620:G:A	NA	NA	Pathogenic	NA	Likely Pathogenic	NA	NA	Likely Pathogenic	NA	High LDLchr19-11113650-G-A	19-11224326-G-A	LDLR	161285	171216	single nucleotide variant	2-Jan-18	13	chr19	11113650	G	A	1/2/18	49960	0	1	1	FALSE	FALSE	NA	chr19:11113650:G:A	NA	NA	Pathogenic	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11113307-C-T	19-11223983-C-T	LDLR	226351	228164	single nucleotide variant	30-Mar-17	9	chr19	11113307	C	T	3/30/17	49960	0	1	1	FALSE	FALSE	NA	chr19:11113307:C:T	NA	NA	Pathogenic	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11111538-A-C	19-11222214-A-C	LDLR	36452	45115	single nucleotide variant	25-Mar-16	6	chr19	11111538	A	C	3/25/16	49960	0	15	15	FALSE	FALSE	NA	chr19:11111538:A:C	NA	NA	VUS	NA	NA	NA	NA	VUS	NA	High LDLchr19-11113557-G-A	19-11224233-G-A	LDLR	36456	45119	single nucleotide variant	18-Aug-11	1	chr19	11113557	G	A	8/18/11	49960	0	1	1	FALSE	FALSE	NA	chr19:11113557:G:A	NA	NA	VUS	NA	NA	NA	NA	VUS	NA	High LDLchr19-11106627-C-T	19-11217303-C-T	LDLR	161261	171200	single nucleotide variant	30-Mar-17	8	chr19	11106627	C	T	3/30/17	49960	0	10	10	FALSE	FALSE	NA	chr19:11106627:C:T	VUS	Insufficient evidence	NA	NA	NA	NA	NA	VUS	Insufficient evidence	High LDLchr19-11123315-C-T	19-11233991-C-T	LDLR	161262	171222	single nucleotide variant	30-Mar-17	9	chr19	11123315	C	T	3/30/17	49960	0	2	2	FALSE	FALSE	NA	chr19:11123315:C:T	VUS	Insufficient evidence	NA	NA	NA	NA	NA	VUS	Insufficient evidence	High LDLchr19-11120483-G-A	19-11231159-G-A	LDLR	183130	181272	single nucleotide variant	7-Jun-17	7	chr19	11120483	G	A	6/7/17	49960	0	5	5	FALSE	FALSE	NA	chr19:11120483:G:A	VUS	Insufficient evidence	NA	NA	NA	NA	NA	VUS	Insufficient evidence	High LDLchr19-11123275-G-A	19-11233951-G-A	LDLR	183133	181275	single nucleotide variant	14-Jun-16	5	chr19	11123275	G	A	6/14/16	49960	0	2	2	FALSE	FALSE	NA	chr19:11123275:G:A	VUS	Insufficient evidence	NA	NA	NA	NA	NA	VUS	Insufficient evidence	High LDLchr19-11105249-C-T	19-11215925-C-T	LDLR	251162	245500	single nucleotide variant	30-Mar-17	4	chr19	11105249	C	T	3/30/17	49960	0	1	1	FALSE	FALSE	NA	chr19:11105249:C:T	NA	NA	VUS	NA	NA	NA	NA	VUS	NA	High LDLchr19-11110660-G-A	19-11221336-G-A	LDLR	251567	245891	single nucleotide variant	30-Mar-17	3	chr19	11110660	G	A	3/30/17	49960	0	11	11	FALSE	FALSE	NA	chr19:11110660:G:A	NA	NA	VUS	NA	NA	NA	NA	VUS	NA	High LDLchr19-11113392-C-T	19-11224068-C-T	LDLR	251775	246089	single nucleotide variant	25-Mar-16	3	chr19	11113392	C	T	3/25/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11113392:C:T	VUS	Insufficient evidence	NA	NA	NA	NA	NA	VUS	Insufficient evidence	High LDLchr19-11113679-G-A	19-11224355-G-A	LDLR	251876	246190	single nucleotide variant	30-Mar-17	2	chr19	11113679	G	A	3/30/17	49960	0	1	1	FALSE	FALSE	NA	chr19:11113679:G:A	NA	NA	VUS	NA	NA	NA	NA	VUS	NA	High LDLchr19-11113767-G-A	19-11224443-G-A	LDLR	251909	246223	single nucleotide variant	25-Apr-17	6	chr19	11113767	G	A	4/25/17	49960	0	2	2	FALSE	FALSE	NA	chr19:11113767:G:A	VUS	Insufficient evidence	NA	NA	NA	NA	NA	VUS	Insufficient evidence	High LDLchr19-11120212-C-A	19-11230888-C-A	LDLR	252136	246432	single nucleotide variant	16-Dec-16	5	chr19	11120212	C	A	12/16/16	49960	0	3	3	FALSE	FALSE	NA	chr19:11120212:C:A	VUS	Insufficient evidence	NA	NA	NA	NA	NA	VUS	Insufficient evidence	High LDLchr19-11120114-T-C	19-11230790-T-C	LDLR	369855	354097	single nucleotide variant	NA	2	chr19	11120114	T	C	NA	49960	0	3	3	FALSE	FALSE	NA	chr19:11120114:T:C	VUS	Insufficient evidence	NA	NA	NA	NA	NA	VUS	Insufficient evidence	High LDLchr19-11100237-G-A	19-11210913-G-A	LDLR	430745	424291	single nucleotide variant	30-Mar-17	2	chr19	11100237	G	A	3/30/17	49960	0	2	2	FALSE	FALSE	NA	chr19:11100237:G:A	VUS	Insufficient evidence	NA	NA	NA	NA	NA	VUS	Insufficient evidence	High LDLchr19-11102705-C-T	19-11213381-C-T	LDLR	161289	171197	single nucleotide variant	25-Mar-16	3	chr19	11102705	C	T	3/25/16	49960	0	3	3	FALSE	FALSE	NA	chr19:11102705:C:T	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia (high LDL)	VUS	NA	High LDLchr19-11113382-G-C	19-11224058-G-C	LDLR	36454	45117	single nucleotide variant	18-Aug-11	1	chr19	11113382	G	C	8/18/11	49960	0	1	1	FALSE	FALSE	NA	chr19:11113382:G:C	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia (high LDL)	VUS	NA	High LDLchr19-11102714-C-T	19-11213390-C-T	LDLR	183083	181222	single nucleotide variant	16-Dec-16	10	chr19	11102714	C	T	12/16/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11102714:C:T	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia (high LDL)	VUS	NA	High LDLchr19-11113686-A-G	19-11224362-A-G	LDLR	183117	181259	single nucleotide variant	30-Mar-17	6	chr19	11113686	A	G	3/30/17	49960	0	2	2	FALSE	FALSE	NA	chr19:11113686:A:G	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia (high LDL)	VUS	NA	High LDLchr19-11113343-G-A	19-11224019-G-A	LDLR	225182	227097	single nucleotide variant	5-Nov-16	5	chr19	11113343	G	A	11/5/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11113343:G:A	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia (high LDL)	VUS	NA	High LDLchr19-11113287-C-A	19-11223963-C-A	LDLR	226350	228163	single nucleotide variant	25-Mar-16	3	chr19	11113287	C	A	3/25/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11113287:C:A	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11116898-T-C	19-11227574-T-C	LDLR	226372	228184	single nucleotide variant	16-Dec-16	4	chr19	11116898	T	C	12/16/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11116898:T:C	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11120106-G-T	19-11230782-G-T	LDLR	226376	228189	single nucleotide variant	25-Mar-16	2	chr19	11120106	G	T	3/25/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11120106:G:T	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11102787-G-C	19-11213463-G-C	LDLR	228358	230978	single nucleotide variant	16-Dec-16	7	chr19	11102787	G	C	12/16/16	49958	2	1	1	FALSE	FALSE	NA	chr19:11102787:G:C	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11102699-G-T	19-11213375-G-T	LDLR	251081	245424	single nucleotide variant	30-Mar-17	4	chr19	11102699	G	T	3/30/17	49960	0	1	1	FALSE	FALSE	NA	chr19:11102699:G:T	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11107461-G-A	19-11218137-G-A	LDLR	251502	245834	single nucleotide variant	16-Dec-16	4	chr19	11107461	G	A	12/16/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11107461:G:A	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11110690-C-T	19-11221366-C-T	LDLR	251583	245907	single nucleotide variant	16-Dec-16	5	chr19	11110690	C	T	12/16/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11110690:C:T	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11111514-A-G	19-11222190-A-G	LDLR	251639	245960	single nucleotide variant	5-Nov-16	4	chr19	11111514	A	G	11/5/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11111514:A:G	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11113600-C-T	19-11224276-C-T	LDLR	251836	246150	single nucleotide variant	16-Dec-16	2	chr19	11113600	C	T	12/16/16	49960	0	1	1	FALSE	FALSE	NA	chr19:11113600:C:T	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11129602-G-T	19-11240278-G-T	LDLR	375840	362732	single nucleotide variant	16-Dec-16	1	chr19	11129602	G	T	12/16/16	49944	16	1	1	FALSE	FALSE	NA	chr19:11129602:G:T	NA	NA	NA	NA	VUS	NA	familial hypercholesterolemia	VUS	NA	High LDLchr19-11111506-T-C	19-11222182-T-C	LDLR	36451	45114	single nucleotide variant	31-May-18	15	chr19	11111506	T	C	5/31/18	49960	0	812	802	TRUE	TRUE	Benign	chr19:11111506:T:C	NA	NA	NA	NA	NA	NA	NA	Benign	NA	High LDLchr19-11120527-G-A	19-11231203-G-A	LDLR	36460	45123	single nucleotide variant	26-Jan-18	13	chr19	11120527	G	A	1/26/18	49960	0	1150	1138	TRUE	TRUE	Benign	chr19:11120527:G:A	NA	NA	NA	NA	NA	NA	NA	Benign	NA	High LDLchr19-11110681-G-A	19-11221357-G-A	LDLR	161263	171207	single nucleotide variant	5-Oct-17	11	chr19	11110681	G	A	10/5/17	49960	0	32	30	TRUE	TRUE	Benign	chr19:11110681:G:A	NA	NA	NA	NA	NA	NA	NA	Benign	NA	High LDLchr19-11107403-G-A	19-11218079-G-A	LDLR	183097	181238	single nucleotide variant	29-Dec-17	12	chr19	11107403	G	A	12/29/17	49960	0	40	40	FALSE	TRUE	Benign	chr19:11107403:G:A	NA	NA	NA	NA	NA	NA	NA	Benign	NA	High LDLchr19-11111624-G-A	19-11222300-G-A	LDLR	183138	181250	single nucleotide variant	18-Aug-17	15	chr19	11111624	G	A	8/18/17	49960	0	5193	4827	TRUE	TRUE	Benign	chr19:11111624:G:A	NA	NA	NA	NA	NA	NA	NA	Benign	NA	High LDLchr19-11110648-G-A	19-11221324-G-A	LDLR	224619	226399	single nucleotide variant	12-Jan-18	10	chr19	11110648	G	A	1/12/18	49960	0	95	95	FALSE	TRUE	Benign	chr19:11110648:G:A	NA	NA	NA	NA	NA	NA	NA	Benign	NA	High LDLchr19-11113285-C-T	19-11223961-C-T	LDLR	224620	226400	single nucleotide variant	2-Jan-18	5	chr19	11113285	C	T	1/2/18	49960	0	18	18	FALSE	TRUE	Benign	chr19:11113285:C:T	NA	NA	NA	NA	NA	NA	NA	Benign	NA	High LDLchr19-11100303-G-T	19-11210979-G-T	LDLR	68099	78990	single nucleotide variant	30-Nov-17	13	chr19	11100303	G	T	11/30/17	49956	4	71	71	FALSE	TRUE	Likely benign	chr19:11100303:G:T	NA	NA	NA	NA	NA	NA	NA	Likely Benign	NA	High LDLchr19-11129564-G-A	19-11240240-G-A	LDLR	161278	171223	single nucleotide variant	17-Nov-17	9	chr19	11129564	G	A	11/17/17	49960	0	10	10	FALSE	TRUE	Likely benign	chr19:11129564:G:A	NA	NA	NA	NA	NA	NA	NA	Likely Benign	NA	High LDLchr19-11106676-G-A	19-11217352-G-A	LDLR	161279	171202	single nucleotide variant	17-Oct-17	13	chr19	11106676	G	A	10/17/17	49960	0	23	23	FALSE	TRUE	Likely benign	chr19:11106676:G:A	Benign	"Functional studies show no damaging effect, Lack of segregation in affected members of a family, observed in cis with a pathogenic variant, Allele frequency is greater than expected for disorder"	NA	NA	NA	NA	NA	Likely Benign	"Functional studies show no damaging effect, Lack of segregation in affected members of a family, observed in cis with a pathogenic variant, Allele frequency is greater than expected for disorder"	High LDLchr19-11113313-G-A	19-11223989-G-A	LDLR	36453	45116	single nucleotide variant	23-Jan-18	12	chr19	11113313	G	A	1/23/18	49960	0	1	1	FALSE	TRUE	Likely pathogenic	chr19:11113313:G:A	NA	NA	NA	NA	NA	NA	NA	Likely Pathogenic	NA	High LDLchr19-11107436-G-A	19-11218112-G-A	LDLR	161268	171204	single nucleotide variant	1-May-18	11	chr19	11107436	G	A	5/1/18	49960	0	1	1	FALSE	TRUE	Likely pathogenic	chr19:11107436:G:A	NA	NA	NA	NA	NA	NA	NA	Likely Pathogenic	NA	High LDLchr19-11113329-C-T	19-11224005-C-T	LDLR	161276	171212	single nucleotide variant	23-Oct-17	9	chr19	11113329	C	T	10/23/17	49960	0	2	2	FALSE	TRUE	Likely pathogenic	chr19:11113329:C:T	NA	NA	NA	NA	NA	NA	NA	Likely Pathogenic	NA	High LDLchr19-11116936-C-T	19-11227612-C-T	LDLR	161290	171218	single nucleotide variant	24-Oct-17	11	chr19	11116936	C	T	10/24/17	49960	0	1	1	FALSE	TRUE	Likely pathogenic	chr19:11116936:C:T	NA	NA	NA	NA	NA	NA	NA	Likely Pathogenic	NA	High LDLchr19-11116873-C-T	19-11227549-C-T	LDLR	183123	181265	single nucleotide variant	11-Dec-17	6	chr19	11116873	C	T	12/11/17	49960	0	3	3	FALSE	TRUE	Likely pathogenic	chr19:11116873:C:T	Likely Pathogenic	High Confidence Lab	NA	NA	NA	NA	NA	Likely Pathogenic	High Confidence Lab	High LDLchr19-11116198-A-G	19-11226874-A-G	LDLR	224616	226401	single nucleotide variant	24-Apr-18	5	chr19	11116198	A	G	4/24/18	49960	0	1	1	FALSE	TRUE	Likely pathogenic	chr19:11116198:A:G	VUS	Insufficient evidence	NA	NA	NA	NA	NA	Likely Pathogenic	Insufficient evidence	High LDLchr19-11105243-G-A	19-11215919-G-A	LDLR	237872	243268	single nucleotide variant	8-Feb-18	4	chr19	11105243	G	A	2/8/18	49960	0	4	4	FALSE	TRUE	Likely pathogenic	chr19:11105243:G:A	VUS	Insufficient evidence	NA	NA	NA	NA	NA	Likely Pathogenic	Insufficient evidence	High LDLchr19-11111586-A-C	19-11222262-A-C	LDLR	183108	181249	single nucleotide variant	30-Mar-17	7	chr19	11111586	A	C	3/30/17	49959	1	1	1	FALSE	TRUE	Likely pathogenic	chr19:11111586:A:C	NA	NA	NA	NA	NA	NA	NA	Likely pathogenic	NA	High LDLchr19-11113590-G-T	19-11224266-G-T	LDLR	183116	181258	single nucleotide variant	4-May-18	9	chr19	11113590	G	T	5/4/18	49957	3	3	3	FALSE	TRUE	Likely pathogenic	chr19:11113590:G:T	NA	NA	NA	NA	NA	NA	NA	Likely pathogenic	NA	High LDLchr19-11113678-C-T	19-11224354-C-T	LDLR	251874	246188	single nucleotide variant	30-Aug-17	5	chr19	11113678	C	T	8/30/17	49960	0	2	2	FALSE	TRUE	Likely pathogenic	chr19:11113678:C:T	NA	NA	NA	NA	NA	NA	NA	Likely Pathogenic	NA	High LDLchr19-11105585-GAC-G	19-11216261-GAC-G	LDLR	3731	18770	deletion	15-Jun-18	10	chr19	11105585	GAC	G	6/15/18	49956	4	2	2	FALSE	TRUE	"Pathogenic, Pathogenic"	chr19:11105585:GAC:G	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11102787-G-A	19-11213463-G-A	LDLR	3736	18775	single nucleotide variant	16-Jul-18	20	chr19	11102787	G	A	7/16/18	49958	2	1	1	FALSE	TRUE	"Pathogenic, Pathogenic"	chr19:11102787:G:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11120442-T-TC	19-11231118-T-TC	LDLR	68103	78994	duplication	29-Dec-17	7	chr19	11120442	T	TC	12/29/17	49960	0	1	1	FALSE	TRUE	"Pathogenic, Pathogenic"	chr19:11120442:T:TC	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11105407-C-A	19-11216083-C-A	LDLR	200918	198011	single nucleotide variant	20-Mar-18	10	chr19	11105407	C	A	3/20/18	49953	7	1	1	FALSE	TRUE	Pathogenic	chr19:11105407:C:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11102739-G-A	19-11213415-G-A	LDLR	226312	228125	single nucleotide variant	26-May-17	3	chr19	11102739	G	A	5/26/17	49960	0	2	2	FALSE	TRUE	Pathogenic	chr19:11102739:G:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11120143-C-T	19-11230819-C-T	LDLR	226379	228192	single nucleotide variant	14-Jan-18	12	chr19	11120143	C	T	1/14/18	49959	1	2	2	FALSE	TRUE	"Pathogenic, Pathogenic"	chr19:11120143:C:T	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11120411-T-C	19-11231087-T-C	LDLR	226384	228197	single nucleotide variant	8-May-18	5	chr19	11120411	T	C	5/8/18	49960	0	1	1	FALSE	TRUE	Pathogenic	chr19:11120411:T:C	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11102683-CG-C	19-11213359-CG-C	LDLR	251078	245421	deletion	14-Feb-18	3	chr19	11102683	CG	C	2/14/18	49958	2	1	1	FALSE	TRUE	Pathogenic	chr19:11102683:CG:C	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11102732-T-G	19-11213408-T-G	LDLR	3685	18724	single nucleotide variant	8-Jun-18	11	chr19	11102732	T	G	6/8/18	49960	0	2	2	FALSE	TRUE	Pathogenic	chr19:11102732:T:G	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11105587-C-G	19-11216263-C-G	LDLR	3690	18729	single nucleotide variant	30-Jun-17	10	chr19	11105587	C	G	6/30/17	49955	5	1	1	FALSE	TRUE	Pathogenic	chr19:11105587:C:G	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11113376-G-A	19-11224052-G-A	LDLR	3694	18733	single nucleotide variant	31-Oct-18	14	chr19	11113376	G	A	10/31/18	49960	0	1	1	FALSE	TRUE	Pathogenic	chr19:11113376:G:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11120436-C-T	19-11231112-C-T	LDLR	3702	18741	single nucleotide variant	31-Oct-18	16	chr19	11120436	C	T	10/31/18	49960	0	6	6	FALSE	TRUE	Pathogenic	chr19:11120436:C:T	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11102774-G-A	19-11213450-G-A	LDLR	161266	171199	single nucleotide variant	31-Oct-18	15	chr19	11102774	G	A	10/31/18	49960	0	6	6	FALSE	TRUE	"Pathogenic, Pathogenic, Pathogenic"	chr19:11102774:G:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11106668-T-A	19-11217344-T-A	LDLR	161287	171201	single nucleotide variant	17-May-18	16	chr19	11106668	T	A	5/17/18	49960	0	1	1	FALSE	TRUE	"Pathogenic, Pathogenic, Pathogenic"	chr19:11106668:T:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11105568-A-G	19-11216244-A-G	LDLR	183092	181233	single nucleotide variant	3-Apr-17	14	chr19	11105568	A	G	4/3/17	49960	0	3	3	FALSE	TRUE	Pathogenic	chr19:11105568:A:G	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11105408-G-A	19-11216084-G-A	LDLR	183136	181228	single nucleotide variant	28-Jun-18	7	chr19	11105408	G	A	6/28/18	49960	0	3	3	FALSE	TRUE	Pathogenic	chr19:11105408:G:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11116900-C-T	19-11227576-C-T	LDLR	200921	198015	single nucleotide variant	23-Jan-18	10	chr19	11116900	C	T	1/23/18	49960	0	1	1	FALSE	TRUE	Pathogenic	chr19:11116900:C:T	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11105556-ATGG-A	19-11216232-ATGG-A	LDLR	226329	228142	deletion	25-Jun-18	14	chr19	11105556	ATGG	A	6/25/18	49960	0	2	2	FALSE	TRUE	"Pathogenic, Pathogenic"	chr19:11105556:ATGG:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11105588-G-T	19-11216264-G-T	LDLR	226333	228146	single nucleotide variant	31-Oct-18	12	chr19	11105588	G	T	10/31/18	49960	0	1	1	FALSE	TRUE	"Pathogenic, Pathogenic"	chr19:11105588:G:T	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11110759-C-T	19-11221435-C-T	LDLR	226342	228156	single nucleotide variant	8-May-18	11	chr19	11110759	C	T	5/8/18	49960	0	3	3	FALSE	TRUE	"Pathogenic, Pathogenic"	chr19:11110759:C:T	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11113268-G-A	19-11223944-G-A	LDLR	226349	228162	single nucleotide variant	30-Mar-17	10	chr19	11113268	G	A	3/30/17	49960	0	1	1	FALSE	TRUE	Pathogenic	chr19:11113268:G:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	NA	High LDLchr19-11110760-G-C	19-11221436-G-C	LDLR	226343	228157	single nucleotide variant	3-Mar-17	3	chr19	11110760	G	C	3/3/17	49960	0	3	3	FALSE	TRUE	Uncertain significance	chr19:11110760:G:C	NA	NA	NA	NA	NA	NA	NA	VUS	NA	High LDLchr19-11116095-T-G	19-11226771-T-G	LDLR	226361	228174	single nucleotide variant	18-Apr-18	2	chr19	11116095	T	G	4/18/18	49960	0	4	2	FALSE	TRUE	Uncertain significance	chr19:11116095:T:G	NA	NA	NA	NA	NA	NA	NA	VUS	NA	High LDLchr19-11129602-G-A	19-11240278-G-A	LDLR	36462	45125	single nucleotide variant	2-Nov-17	16	chr19	11129602	G	A	11/2/17	49959	1	16	16	FALSE	TRUE	"Uncertain significance, Likely benign"	chr19:11129602:G:A	NA	NA	NA	NA	NA	NA	NA	VUS	NA	High LDLchr19-11116969-G-T	19-11227645-G-T	LDLR	161264	171219	single nucleotide variant	25-Oct-17	9	chr19	11116969	G	T	10/25/17	49960	0	33	33	FALSE	TRUE	Uncertain significance	chr19:11116969:G:T	NA	NA	NA	NA	NA	NA	NA	VUS	NA	High LDLchr19-11120122-G-A	19-11230798-G-A	LDLR	183127	181269	single nucleotide variant	27-Sep-17	9	chr19	11120122	G	A	9/27/17	49960	0	16	16	TRUE	TRUE	Uncertain significance	chr19:11120122:G:A	VUS	"Conflicting, but VUS by high confidence lab after Jan 2017"	NA	NA	NA	NA	NA	VUS	"Conflicting, but VUS by high confidence lab after Jan 2017"	High LDLchr19-11116989-C-T	19-11227665-C-T	LDLR	224618	226402	single nucleotide variant	27-Jun-17	9	chr19	11116989	C	T	6/27/17	49959	1	21	21	TRUE	TRUE	Uncertain significance	chr19:11116989:C:T	NA	NA	NA	NA	NA	NA	NA	VUS	NA	High LDLchr19-11106639-C-T	19-11217315-C-T	LDLR	251446	245782	single nucleotide variant	29-Jun-18	8	chr19	11106639	C	T	6/29/18	49960	0	1	1	FALSE	TRUE	Uncertain significance	chr19:11106639:C:T	NA	NA	NA	NA	NA	NA	NA	VUS	NA	High LDLchr19-11110714-G-A	19-11221390-G-A	LDLR	183105	181246	single nucleotide variant	13-May-18	10	chr19	11110714	G	A	5/13/18	49960	0	2	2	FALSE	TRUE	"Likely pathogenic, Uncertain significance"	chr19:11110714:G:A	NA	NA	NA	NA	VUS	"Probably would have used PM2_supporting for this, check on bs3 and bp5"	familial hypercholesterolemia (high LDL)	VUS	"Probably would have used PM2_supporting for this, check on bs3 and bp5"	High LDLchr1-55058549-C-T	1-55524222-C-T	PCSK9	201128	196756	single nucleotide variant	7-Dec-17	5	chr1	55058549	C	T	12/7/17	49960	0	21	21	FALSE	FALSE	"Benign, Uncertain significance"	chr1:55058549:C:T	NA	NA	NA	NA	NA	NA	"hypercholesterolemia, autosomal dominant, 3 (High LDL)"	VUS	NA	High LDLchr1-55039931-G-A	1-55505604-G-A	PCSK9	297692	281418	single nucleotide variant	14-Jun-16	3	chr1	55039931	G	A	6/14/16	49960	0	1	1	FALSE	FALSE	NA	chr1:55039931:G:A	VUS	Conflicting evidence	NA	NA	VUS	variant curated for high LDL	Familial hypercholesterolemia	VUS	"Conflicting evidence, variant curated for high LDL"	High LDLchr1-55058538-C-T	1-55524211-C-T	PCSK9	403292	389422	single nucleotide variant	5-Dec-17	3	chr1	55058538	C	T	12/5/17	49960	0	1	1	TRUE	FALSE	Likely pathogenic	chr1:55058538:C:T	Likely Pathogenic	High Confidence Lab	NA	NA	NA	High Confidence Lab	"hypercholesterolemia, autosomal dominant, 3 (High LDL)"	VUS	Reassessed because PCSK9 missense variants are typically for Low LDL	High LDLchr1-55057454-G-T	1-55523127-G-T	PCSK9	2875	17914	single nucleotide variant	2-Jan-18	5	chr1	55057454	G	T	1/2/18	49957	3	1	1	FALSE	FALSE	NA	chr1:55057454:G:T	NA	NA	NA	NA	Pathogenic	GoF mechanism; increased penetrance compared to other PCSK9 variants or variants in other FH-causing genes	"hypercholesterolemia, autosomal dominant, 3"	Pathogenic	GoF mechanism; increased penetrance compared to other PCSK9 variants or variants in other FH-causing genes	High LDLchr1-55052701-C-T	1-55518374-C-T	PCSK9	265933	260609	single nucleotide variant	25-Jul-17	5	chr1	55052701	C	T	7/25/17	49960	0	147	147	FALSE	FALSE	NA	chr1:55052701:C:T	NA	NA	VUS	NA	NA	NA	"Familial hypercholesterolemia;Hypercholesterolemia, autosomal dominant, 3"	VUS	NA	High LDLchr1-55058106-C-A	1-55523779-C-A	PCSK9	369875	354066	single nucleotide variant	16-Dec-16	2	chr1	55058106	C	A	12/16/16	49960	0	11	11	FALSE	FALSE	NA	chr1:55058106:C:A	NA	NA	VUS	NA	NA	NA	Familial hypercholesterolemia_	VUS	NA	High LDLchr11-116790940-G-A	11-116661656-G-A	APOA5	381733	371260	single nucleotide variant	1-Feb-17	1	chr11	116790940	G	A	2/1/17	49960	0	30	30	FALSE	TRUE	Pathogenic	chr11:116790940:G:A	Pathogenic	High Confidence Lab	NA	NA	Pathogenic	NA	hypertriglyceridemia	Pathogenic	High Confidence Lab	High triglycerideschr8-19955849-C-T	8-19813360-C-T	LPL	523886	514566	single nucleotide variant	27-Apr-18	1	chr8	19955849	C	T	4/27/18	49960	0	1	1	FALSE	FALSE	NA	chr8:19955849:C:T	NA	NA	NA	NA	VUS	"Variant seems like it should be curated for a recessive trait, comp hets are severely affected but hets are unaffected"	hypertriglyceridemia (disease)	VUS	"Variant seems like it should be curated for a recessive trait, comp hets are severely affected but hets are unaffected"	High triglycerideschr8-19954222-G-A	8-19811733-G-A	LPL	1522	16561	single nucleotide variant	31-Oct-18	3	chr8	19954222	G	A	10/31/18	49960	0	44	44	FALSE	FALSE	NA	chr8:19954222:G:A	NA	NA	NA	NA	VUS	NA	"hyperlipidemia, familial combined"	VUS	NA	High triglycerideschr8-19954240-T-C	8-19811751-T-C	LPL	1529	16568	single nucleotide variant	14-Jun-16	2	chr8	19954240	T	C	6/14/16	49958	2	1	1	FALSE	FALSE	NA	chr8:19954240:T:C	NA	NA	NA	NA	VUS	NA	"hyperlipidemia, familial combined"	VUS	NA	High triglycerideschr8-19955874-G-A	8-19813385-G-A	LPL	1530	16569	single nucleotide variant	29-Jun-17	2	chr8	19955874	G	A	6/29/17	49960	0	1	1	FALSE	FALSE	NA	chr8:19955874:G:A	NA	NA	NA	NA	VUS	NA	"hyperlipidemia, familial combined"	VUS	NA	High triglycerideschr1-156138507-C-T	1-156108298-C-T	LMNA	14517	29556	single nucleotide variant	21-Dec-17	7	chr1	156138507	C	T	12/21/17	49960	0	3	3	TRUE	FALSE	NA	chr1:156138507:C:T	NA	NA	NA	NA	Benign	"The p.Ser573Leu variant in LMNA has been reported in 1 European individual with familial partial lipodystrophy (PMID: 17250669), but has been identified in 0.04% (4/10102) of Ashkenazi Jewish chromosomes and other populations at slightly lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs60890628). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 14517). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, this variant meets criteria to be classified as benign for familial partial lipodystrophy in an autosomal dominant manner based on its frequency in the general population. ACMG/AMP Criteria applied: BA1 (Richards 2015)."	familial partial lipodystrophy	Benign	"The p.Ser573Leu variant in LMNA has been reported in 1 European individual with familial partial lipodystrophy (PMID: 17250669), but has been identified in 0.04% (4/10102) of Ashkenazi Jewish chromosomes and other populations at slightly lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs60890628). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 14517). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, this variant meets criteria to be classified as benign for familial partial lipodystrophy in an autosomal dominant manner based on its frequency in the general population. ACMG/AMP Criteria applied: BA1 (Richards 2015)."	"Lipodystrophy, MonogenicDM_all"chr1-156136984-C-T	1-156106775-C-T	LMNA	14489	29528	single nucleotide variant	14-Nov-14	3	chr1	156136984	C	T	11/14/14	49960	0	1	1	FALSE	FALSE	NA	chr1:156136984:C:T	NA	NA	NA	NA	Pathogenic	"The p.Arg482Trp variant in LMNA has been reported in at least 12 European individuals with familial partial lipodystrophy, segregated with disease in at least 7 affected relatives from 2 families (PMID: 15531479, 10655060,11344241), and has been identified in 0.0009% (1/113640) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs57920071). This variant has also been reported in ClinVar as pathogenic (Variation ID: 14489). In vitro functional studies provide some evidence that the p.Arg482Trp variant may slightly impact protein function (PMID: 25524705). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional likely pathogenic and one pathogenic variant, resulting in a different amino acid change at the same position, p.Arg482Leu and p.Arg482Gln, have been reported in association with disease in the literature and ClinVar, supporting that a change at this position may not be tolerated (PMID: 10655060, 14597414, 19201734, 23313286, 10587585, 20130076, 28492532 /Variation ID: 14490 and 14486). In summary, this variant meets criteria to be classified as pathogenic for familial partial lipodystrophy in an autosomal dominant manner based on cosegregation with disease in multiple affected families and the prevalence of this variant in many affected individuals. ACMG/AMP Criteria applied: PP1_strong, PS4_moderate, PM5, PM2, PP3, PS3_supporting (Richards 2015)."	lipodystrophy	Pathogenic	"The p.Arg482Trp variant in LMNA has been reported in at least 12 European individuals with familial partial lipodystrophy, segregated with disease in at least 7 affected relatives from 2 families (PMID: 15531479, 10655060,11344241), and has been identified in 0.0009% (1/113640) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs57920071). This variant has also been reported in ClinVar as pathogenic (Variation ID: 14489). In vitro functional studies provide some evidence that the p.Arg482Trp variant may slightly impact protein function (PMID: 25524705). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional likely pathogenic and one pathogenic variant, resulting in a different amino acid change at the same position, p.Arg482Leu and p.Arg482Gln, have been reported in association with disease in the literature and ClinVar, supporting that a change at this position may not be tolerated (PMID: 10655060, 14597414, 19201734, 23313286, 10587585, 20130076, 28492532 /Variation ID: 14490 and 14486). In summary, this variant meets criteria to be classified as pathogenic for familial partial lipodystrophy in an autosomal dominant manner based on cosegregation with disease in multiple affected families and the prevalence of this variant in many affected individuals. ACMG/AMP Criteria applied: PP1_strong, PS4_moderate, PM5, PM2, PP3, PS3_supporting (Richards 2015)."	"Lipodystrophy, MonogenicDM_all"chr1-156137679-G-A	1-156107470-G-A	LMNA	163878	172489	single nucleotide variant	23-Apr-18	7	chr1	156137679	G	A	4/23/18	49960	0	39	39	TRUE	FALSE	NA	chr1:156137679:G:A	NA	NA	NA	NA	VUS	"Assessed by HC lab, but reassessed due to high frequency; Uncertain significance - conflicting evidence:  The p.Arg545His variant in LMNA has been reported in 1 individual with lipodystrophy (PMID: 28074886), but has been identified in 0.05% (41/79748) of European (non-Finnish) chromosomes and other populations at lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP  rs142191737). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 163878). In vitro functional studies provide some evidence that the p.Arg545His variant may slightly impact protein function (PMID: 22918509). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Arg545His have been reported in association with disease in the literature and the variant is located in a region of LMNA that is thought to be essential to protein folding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 28663758). In summary, the clinical significance of the p.Arg545His variant is uncertain. ACMG/AMP Criteria applied: PP3, PS3_supporting, PM1_supporting, BA1 (Richards 2015)."	lipodystrophy	VUS	"Assessed by HC lab, but reassessed due to high frequency; Uncertain significance - conflicting evidence:  The p.Arg545His variant in LMNA has been reported in 1 individual with lipodystrophy (PMID: 28074886), but has been identified in 0.05% (41/79748) of European (non-Finnish) chromosomes and other populations at lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP  rs142191737). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 163878). In vitro functional studies provide some evidence that the p.Arg545His variant may slightly impact protein function (PMID: 22918509). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Arg545His have been reported in association with disease in the literature and the variant is located in a region of LMNA that is thought to be essential to protein folding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 28663758). In summary, the clinical significance of the p.Arg545His variant is uncertain. ACMG/AMP Criteria applied: PP3, PS3_supporting, PM1_supporting, BA1 (Richards 2015)., After reassessment this variant is given a VUS assessment"	"Lipodystrophy, MonogenicDM_all"chr11-17404552-C-T	11-17426099-C-T	ABCC8	35609	44274	single nucleotide variant	1-Jan-17	2	chr11	17404552	C	T	1/1/17	49960	0	4	4	FALSE	FALSE	NA	chr11:17404552:C:T	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Val1173Met variant in ABCC8 has been reported in 1 individual with Monogenic Diabetes in ClinVar (Variation ID: 35609), and has been identified in 0.003098% (4/129110) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs141322087). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 35609). Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the p.Val1173Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, BP4 (Richards 2015)."	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Val1173Met variant in ABCC8 has been reported in 1 individual with Monogenic Diabetes in ClinVar (Variation ID: 35609), and has been identified in 0.003098% (4/129110) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs141322087). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 35609). Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the p.Val1173Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, BP4 (Richards 2015)."	"MODY Extended, MonogenicDM_all, Neonatal Diabetes"chr11-17412716-G-A	11-17434263-G-A	ABCC8	188915	186816	single nucleotide variant	31-Oct-18	5	chr11	17412716	G	A	10/31/18	49960	0	1	1	FALSE	FALSE	NA	chr11:17412716:G:A	NA	NA	NA	NA	VUS	Variant assocaited only with Hyperinsulemic hyperglycemia in the literature	Hyperinsulemic hyperglycemia	NA	Variant assocaited only with Hyperinsulemic hyperglycemia in the literature	"MODY Extended, MonogenicDM_all, Neonatal Diabetes"chr11-17387211-G-A	11-17408758-G-A	KCNJ11	211230	207832	single nucleotide variant	18-Aug-17	2	chr11	17387211	G	A	8/18/17	49960	0	1	1	FALSE	FALSE	NA	chr11:17387211:G:A	NA	NA	NA	NA	NA	NA	NA	NA	Phenotype of available literature doesn't fit	"MODY Extended, MonogenicDM_all, Neonatal Diabetes"chr11-17387532-G-A	11-17409079-G-A	KCNJ11	551187	546193	single nucleotide variant	21-Mar-17	1	chr11	17387532	G	A	3/21/17	49960	0	1	1	FALSE	FALSE	NA	chr11:17387532:G:A	NA	NA	NA	NA	VUS	Variant assocaited only with CHI in the literature	hyperinsulinism	NA	Variant assocaited only with CHI in the literature	"MODY Extended, MonogenicDM_all, Neonatal Diabetes"chr7-44153381-C-T	7-44192980-C-T	GCK	393453	380272	single nucleotide variant	21-Dec-17	2	chr7	44153381	C	T	12/21/17	49960	0	1	1	FALSE	FALSE	NA	chr7:44153381:C:T	NA	NA	Likely Pathogenic	"The p.Arg43His variant in GCK has been reported in at least 8 individuals (including 1 German, 1 Slovakian, 1 Swiss, 1 Cyproit, and 1 Hispanic individuals) with Monogenic Diabetes, segregated with disease in 6 affected relatives from 2 family (PMID: 11942313, 24430320, 11942313, 22611063, 22493702, 27106716; DOI:10.3252/pso.eu.54espe.2015; Shammas et al. 2012), and has been identified in 0.002891% (1/34592) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs764232985). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 393453). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional pathogenic variant, resulting in a different amino acid change at the same position, p.Arg43Cys, has been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 21348868, 30592380, 21521320, 23771172, 19790256, 25015100/Variation ID: 585911). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PS4_Moderate, PM5, PM2_Supporting, PP3, PP1_moderate (Richards 2015)."	NA	NA	NA	Likely Pathogenic	"The p.Arg43His variant in GCK has been reported in at least 8 individuals (including 1 German, 1 Slovakian, 1 Swiss, 1 Cyproit, and 1 Hispanic individuals) with Monogenic Diabetes, segregated with disease in 6 affected relatives from 2 family (PMID: 11942313, 24430320, 11942313, 22611063, 22493702, 27106716; DOI:10.3252/pso.eu.54espe.2015; Shammas et al. 2012), and has been identified in 0.002891% (1/34592) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs764232985). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 393453). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional pathogenic variant, resulting in a different amino acid change at the same position, p.Arg43Cys, has been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 21348868, 30592380, 21521320, 23771172, 19790256, 25015100/Variation ID: 585911). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PS4_Moderate, PM5, PM2_Supporting, PP3, PP1_moderate (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr7-44150004-C-T	7-44189603-C-T	GCK	129144	134590	single nucleotide variant	31-Oct-18	5	chr7	44150004	C	T	10/31/18	49960	0	2	2	FALSE	FALSE	NA	chr7:44150004:C:T	NA	NA	NA	NA	Pathogenic	"The p.Val182Met variant in GCK has been reported in at least 9 individuals with maturity-onset diabetes of the young (MODY) type 2, segregated with disease in 4 affected relatives from 2 families (PMID: 29510678, 20337973, 21395678, 25082184, 23771172, 25306193, 25494859), and was absent from large population studies. Animal models in mice have shown that this variant causes MODY type 2 (15102714, 18056790). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, this variant meets criteria to be classified as pathogenic for MODY type 2 in an autosomal dominant manner based on the phenotype of mouse models being consistent with human disease, the increased prevalence of the variant in affected individuals, including relatives, compared to controls, and computational evidence. ACMG/AMP Criteria applied: PS3_PM2, PS4_moderate, PP3, PP1 (Richards 2015)."	maturity-onset diabetes of the young type 2	Pathogenic	"The p.Val182Met variant in GCK has been reported in at least 9 individuals with maturity-onset diabetes of the young (MODY) type 2, segregated with disease in 4 affected relatives from 2 families (PMID: 29510678, 20337973, 21395678, 25082184, 23771172, 25306193, 25494859), and was absent from large population studies. Animal models in mice have shown that this variant causes MODY type 2 (15102714, 18056790). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, this variant meets criteria to be classified as pathogenic for MODY type 2 in an autosomal dominant manner based on the phenotype of mouse models being consistent with human disease, the increased prevalence of the variant in affected individuals, including relatives, compared to controls, and computational evidence. ACMG/AMP Criteria applied: PS3_PM2, PS4_moderate, PP3, PP1 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr7-44151069-C-T	7-44190668-C-T	GCK	211073	207484	single nucleotide variant	1-Jun-17	2	chr7	44151069	C	T	6/1/17	49960	0	3	3	FALSE	FALSE	NA	chr7:44151069:C:T	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Asp124Asn variant in GCK has been reported in at least 6 individuals (including 1 Polish, 1 Czech, 1 German, and 2 Caucasian individuals) with Monogenic Diabetes (PMID: 27106716, 22773699, 24918535, 20337973; DOI: 10.2337/db18-1509-P), and has been identified in 0.002893% (1/34564) of Latino chromosomes and 0.0008805% (1/113574) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs759072800). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 211073). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The number of missense variants reported in GCK in the general population is lower than expected, suggesting there is little benign variation in this gene and slightly increasing the possibility that a missense variant in this gene may not be tolerated. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PS4_Moderate, PM2_Supporting, PP2, PP3 (Richards 2015)."	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Asp124Asn variant in GCK has been reported in at least 6 individuals (including 1 Polish, 1 Czech, 1 German, and 2 Caucasian individuals) with Monogenic Diabetes (PMID: 27106716, 22773699, 24918535, 20337973; DOI: 10.2337/db18-1509-P), and has been identified in 0.002893% (1/34564) of Latino chromosomes and 0.0008805% (1/113574) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs759072800). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 211073). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The number of missense variants reported in GCK in the general population is lower than expected, suggesting there is little benign variation in this gene and slightly increasing the possibility that a missense variant in this gene may not be tolerated. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PS4_Moderate, PM2_Supporting, PP2, PP3 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr7-44145543-G-C	7-44185142-G-C	GCK	36187	44851	single nucleotide variant	18-Aug-11	1	chr7	44145543	G	C	8/18/11	49960	0	1	1	FALSE	FALSE	NA	chr7:44145543:G:C	NA	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Arg403Gly variant in GCK has not been previously reported in individuals with maturity-onset diabetes of the young type 2 and was absent from large population studies. This variant has been reported in ClinVar (VariationID: 36187) as likely pathogenic by Integrated Genetics Laboratory. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein.  In summary, the clinical significance of the p.Arg403Gly variant is uncertain. ACMG/AMP Criteria applied: PM2 (Richards 2015)."	maturity-onset diabetes of the young type 2	VUS	"Uncertain significance - insufficient evidence: The p.Arg403Gly variant in GCK has not been previously reported in individuals with maturity-onset diabetes of the young type 2 and was absent from large population studies. This variant has been reported in ClinVar (VariationID: 36187) as likely pathogenic by Integrated Genetics Laboratory. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein.  In summary, the clinical significance of the p.Arg403Gly variant is uncertain. ACMG/AMP Criteria applied: PM2 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr7-44145148-C-A	7-44184747-C-A	GCK	36202	44866	single nucleotide variant	29-May-18	2	chr7	44145148	C	A	5/29/18	49960	0	22	22	FALSE	FALSE	NA	chr7:44145148:C:A	NA	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Met462Ile variant in GCK has not been previously reported in individuals with maturity-onset diabetes of the young (MODY) type 2 but has been identified in 0.004028% (5/124138) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922285). This variant has also been reported in ClinVar (VariationID: 36202) as a VUS by Athena Diagnostics Inc and as likely pathogenic by Integrated Genetics; the former lab also reported one individual with the variant and MODY type 2. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein.  In summary, the clinical significance of the p.Met462Ile variant is uncertain. ACMG/AMP Criteria applied: BS1 (Richards 2015)."	maturity-onset diabetes of the young type 2	VUS	"Uncertain significance - insufficient evidence: The p.Met462Ile variant in GCK has not been previously reported in individuals with maturity-onset diabetes of the young (MODY) type 2 but has been identified in 0.004028% (5/124138) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922285). This variant has also been reported in ClinVar (VariationID: 36202) as a VUS by Athena Diagnostics Inc and as likely pathogenic by Integrated Genetics; the former lab also reported one individual with the variant and MODY type 2. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein.  In summary, the clinical significance of the p.Met462Ile variant is uncertain. ACMG/AMP Criteria applied: BS1 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr7-44147765-G-A	7-44187364-G-A	GCK	393451	380270	single nucleotide variant	21-Sep-17	2	chr7	44147765	G	A	9/21/17	49960	0	2	2	FALSE	FALSE	NA	chr7:44147765:G:A	NA	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Arg250Cys variant in GCK has been reported in at least 5 families with MODY (PMID: 15448103, 20337973, 19790256) and was absent from large population studies. This variant has also been reported in ClinVar (VariationID: 393451) as likely pathogenic by Translational Genomics Laboratory and as a VUS by Athena Diagnostics Inc. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2, PP3, PS4_supporting (Richards 2015)."	maturity-onset diabetes of the young type 2	VUS	"Uncertain significance - insufficient evidence: The p.Arg250Cys variant in GCK has been reported in at least 5 families with MODY (PMID: 15448103, 20337973, 19790256) and was absent from large population studies. This variant has also been reported in ClinVar (VariationID: 393451) as likely pathogenic by Translational Genomics Laboratory and as a VUS by Athena Diagnostics Inc. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2, PP3, PS4_supporting (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr7-44149992-G-A	7-44189591-G-A	GCK	16133	31172	single nucleotide variant	1-Oct-18	3	chr7	44149992	G	A	10/1/18	49959	1	1	1	FALSE	TRUE	Pathogenic	chr7:44149992:G:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	Used HC lab assessment	"MODY, MODY Extended, MonogenicDM_all"chr7-44147830-G-A	7-44187429-G-A	GCK	16134	31173	single nucleotide variant	12-Jun-17	4	chr7	44147830	G	A	6/12/17	49960	0	1	1	FALSE	TRUE	Pathogenic	chr7:44147830:G:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	Used HC lab assessment	"MODY, MODY Extended, MonogenicDM_all"chr7-44149977-G-A	7-44189576-G-A	GCK	426122	415104	single nucleotide variant	7-Nov-17	3	chr7	44149977	G	A	11/7/17	49960	0	2	2	FALSE	TRUE	Pathogenic	chr7:44149977:G:A	NA	NA	NA	NA	NA	NA	NA	Pathogenic	Used HC lab assessment	"MODY, MODY Extended, MonogenicDM_all"chr12-120989032-C-T	12-121426835-C-T	HNF1A	372380	360075	single nucleotide variant	6-Apr-16	1	chr12	120989032	C	T	4/6/16	49960	0	1	1	FALSE	FALSE	NA	chr12:120989032:C:T	NA	NA	NA	NA	Pathogenic	"The p.Gln176Ter variant in HNF1A has been reported in 1 Southern Chinese family with maturity-onset diabetes of the young type 3 (MODY3) and has been identified in 0.0008856% (1/112922) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs754728827). This variant has also been reported in ClinVar (VariationID: 372380) as pathogenic by GeneDx. In vitro functional studies in HeLa cells transfected with the variant demonstrating null expression and transactivation activities similar to those of an empty vector alone provide some evidence that the p.Gln176Ter variant may impact protein function  (PMID: 12107757). However, these types of assays may not accurately represent biological function. This nonsense variant leads to a premature termination codon at position 576, which is predicted to lead to a truncated or absent protein. Heterozygous loss of function of the HNF1A gene is an established disease mechanism in MODY3. In summary, this variant meets criteria to be classified as pathogenic for MODY3 in an autosomal dominant manner based on the prediction that it will cause loss of function of the HNF1A gene, low frequency of the variant in the general population, and in vitro functional studies. ACMG/AMP Criteria applied: PVS1, PM2, PS3_moderate (Richards 2015)."	maturity-onset diabetes of the young type 3	Pathogenic	"The p.Gln176Ter variant in HNF1A has been reported in 1 Southern Chinese family with maturity-onset diabetes of the young type 3 (MODY3) and has been identified in 0.0008856% (1/112922) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs754728827). This variant has also been reported in ClinVar (VariationID: 372380) as pathogenic by GeneDx. In vitro functional studies in HeLa cells transfected with the variant demonstrating null expression and transactivation activities similar to those of an empty vector alone provide some evidence that the p.Gln176Ter variant may impact protein function  (PMID: 12107757). However, these types of assays may not accurately represent biological function. This nonsense variant leads to a premature termination codon at position 576, which is predicted to lead to a truncated or absent protein. Heterozygous loss of function of the HNF1A gene is an established disease mechanism in MODY3. In summary, this variant meets criteria to be classified as pathogenic for MODY3 in an autosomal dominant manner based on the prediction that it will cause loss of function of the HNF1A gene, low frequency of the variant in the general population, and in vitro functional studies. ACMG/AMP Criteria applied: PVS1, PM2, PS3_moderate (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr12-120997491-GCA-G	12-121435294-GCA-G	HNF1A	617650	609054	deletion	17-Apr-18	1	chr12	120997491	GCA	G	4/17/18	49960	0	1	1	FALSE	FALSE	NA	chr12:120997491:GCA:G	NA	NA	NA	NA	Pathogenic	"The p.Gln444Glufs variant in HNF1a has been reported in 5 families with maturity-onset diabetes of the young type 3 (MODY3) and has been  identified in 0.0008888% (1/112510) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs776793516). This variant has also been reported in ClinVar (VariationID: 617650) as pathogenic by the Translational Genomics Laboratory.  This variant is predicted to cause a frameshift, which alters the proteins amino acid sequence beginning at position 444 and leads to a premature termination codon 104 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the HNF1A gene is an established disease mechanism in MODY3. In summary, this variant meets criteria to be classified as pathogenic for MODY3 in an autosomal dominant manner based on the prediction that it causes loss of function of the HNF1A gene and the increased prevalence of the variant in affected individuals compared with controls. ACMG/AMP Criteria applied: PVS1, PM2, PS4_supporting (Richards 2015)."	maturity-onset diabetes of the young type 3	Pathogenic	"The p.Gln444Glufs variant in HNF1a has been reported in 5 families with maturity-onset diabetes of the young type 3 (MODY3) and has been  identified in 0.0008888% (1/112510) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs776793516). This variant has also been reported in ClinVar (VariationID: 617650) as pathogenic by the Translational Genomics Laboratory.  This variant is predicted to cause a frameshift, which alters the proteins amino acid sequence beginning at position 444 and leads to a premature termination codon 104 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the HNF1A gene is an established disease mechanism in MODY3. In summary, this variant meets criteria to be classified as pathogenic for MODY3 in an autosomal dominant manner based on the prediction that it causes loss of function of the HNF1A gene and the increased prevalence of the variant in affected individuals compared with controls. ACMG/AMP Criteria applied: PVS1, PM2, PS4_supporting (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr12-120999604-A-G	12-121437407-A-G	HNF1A	36811	45472	single nucleotide variant	18-Aug-11	1	chr12	120999604	A	G	8/18/11	49960	0	3	3	FALSE	FALSE	NA	chr12:120999604:A:G	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.His582Arg variant in HNF1A has been reported in at least 2 individuals (including 1 Norwegian individual) with Monogenic Diabetes (PMID: 23624530, 27913849, 23348805), and has been identified in 0.01166% (4/34300) of Latino chromosomes, 0.006571% (1/15218) of African chromosomes, and 0.005645% (6/106288) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922589). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and as a VUS in the literature (Variation ID: 36811; PMID: 27080136). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.His582Arg variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PS4_Supporting (Richards 2015)."	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.His582Arg variant in HNF1A has been reported in at least 2 individuals (including 1 Norwegian individual) with Monogenic Diabetes (PMID: 23624530, 27913849, 23348805), and has been identified in 0.01166% (4/34300) of Latino chromosomes, 0.006571% (1/15218) of African chromosomes, and 0.005645% (6/106288) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922589). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and as a VUS in the literature (Variation ID: 36811; PMID: 27080136). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.His582Arg variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PS4_Supporting (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr12-120988973-C-T	12-121426776-C-T	HNF1A	36822	45483	single nucleotide variant	18-Aug-11	1	chr12	120988973	C	T	8/18/11	49960	0	1	1	FALSE	FALSE	NA	chr12:120988973:C:T	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Thr156Met variant in HNF1A has been reported in one individual with Monogenic Diabetes in ClinVar (Variation ID: 36822), and has been identified in 0.01960% (6/30616) of South Asian chromosomes and 0.01129% (4/35434) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs150513055). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36822). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Thr156Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015)."	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Thr156Met variant in HNF1A has been reported in one individual with Monogenic Diabetes in ClinVar (Variation ID: 36822), and has been identified in 0.01960% (6/30616) of South Asian chromosomes and 0.01129% (4/35434) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs150513055). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36822). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Thr156Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr12-120994322-C-G	12-121432125-C-G	HNF1A	36833	45494	single nucleotide variant	18-Aug-11	1	chr12	120994322	C	G	8/18/11	49955	5	3	3	FALSE	FALSE	NA	chr12:120994322:C:G	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Pro291Arg variant in HNF1A has been reported in at least one individual with Monogenic Diabetes in ClinVar (Variation ID: 36833), and has been identified in 0.03450% (8/23188) of African chromosomes and 0.0008106% (1/123362) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922606). This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36833). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. Another variant at the same position, p.Pro291Ser, has been reported benign in ClinVar (Variation ID: 447505). In summary, the clinical significance of the p.Pro291Arg variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting (Richards 2015)."	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Pro291Arg variant in HNF1A has been reported in at least one individual with Monogenic Diabetes in ClinVar (Variation ID: 36833), and has been identified in 0.03450% (8/23188) of African chromosomes and 0.0008106% (1/123362) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922606). This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36833). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. Another variant at the same position, p.Pro291Ser, has been reported benign in ClinVar (Variation ID: 447505). In summary, the clinical significance of the p.Pro291Arg variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr12-120978797-C-T	12-121416600-C-T	HNF1A	435422	429373	single nucleotide variant	13-Feb-15	1	chr12	120978797	C	T	2/13/15	49960	0	2	2	FALSE	FALSE	NA	chr12:120978797:C:T	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Thr10Met variant in HNF1A has been reported in at least 3 individuals with Monogenic Diabetes (PMID: 16917892, 18003757, 28938416), and has been identified in 0.01290% (2/15504) of African chromosomes, 0.005794% (2/34520) of Latino chromosomes, and 0.005473% (1/18270) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs774637975). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.Thr10Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PS4_Supporting (Richards 2015)."	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Thr10Met variant in HNF1A has been reported in at least 3 individuals with Monogenic Diabetes (PMID: 16917892, 18003757, 28938416), and has been identified in 0.01290% (2/15504) of African chromosomes, 0.005794% (2/34520) of Latino chromosomes, and 0.005473% (1/18270) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs774637975). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.Thr10Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PS4_Supporting (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr12-120999522-C-T	12-121437325-C-T	HNF1A	36808	45469	single nucleotide variant	18-Aug-11	1	chr12	120999522	C	T	8/18/11	49960	0	5	5	FALSE	FALSE	NA	chr12:120999522:C:T	NA	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Leu555Phe variant in HNF1A has been reported in 1 individual with maturity-onset diabetes of the young type 3 (PMID: 18003757) and has been identified in 0.001797% (2/111302) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922587). This variant has also been reported in ClinVar (VariationID: 36808) as likely pathogenic by Integrated Genetics. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. One affected individual with this variant have an alternative molecular basis for maturity-onset diabetes of the young, suggesting that this variant may not be pathogenic (PMID: 22341299). In summary, the clinical significance of the p.Leu555Phe variant is uncertain. ACMG/AMP Criteria applied: PM2, BP5 (Richards 2015)."	maturity-onset diabetes of the young type 3	VUS	"Uncertain significance - insufficient evidence: The p.Leu555Phe variant in HNF1A has been reported in 1 individual with maturity-onset diabetes of the young type 3 (PMID: 18003757) and has been identified in 0.001797% (2/111302) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922587). This variant has also been reported in ClinVar (VariationID: 36808) as likely pathogenic by Integrated Genetics. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. One affected individual with this variant have an alternative molecular basis for maturity-onset diabetes of the young, suggesting that this variant may not be pathogenic (PMID: 22341299). In summary, the clinical significance of the p.Leu555Phe variant is uncertain. ACMG/AMP Criteria applied: PM2, BP5 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr12-120994314-G-GC	12-121432117-G-GC	HNF1A	14927	29966	duplication	6-Nov-17	4	chr12	120994314	G	GC	11/6/17	24710	25250	1	1	FALSE	TRUE	Pathogenic	chr12:120994314:G:GC	NA	NA	NA	NA	NA	VUS	"Reassesed because of high no callrate and AF in gnomAD, and gnomAD filtering by random forest"	NA	"After reassessment High frequency in gnomAD (https://gnomad.broadinstitute.org/variant/12-121432117-G-GC). Variant is a frameshift (insertion of C) in a hompolymer. In gnomAD it failed random forest for exomes and genomes. It is described as path by multiple submitters in ClinVar. It reaches pathogenic, but reads in gnomAD and AMP T2D carriers look suspicious. Variant excluded in LoF curation as homopolymer error. The variant may well be real in some individuals, we can't trust the overall genotyping so this variant was excluded from the analysis."	"MODY, MODY Extended, MonogenicDM_all"chr12-120996568-C-G	12-121434371-C-G	HNF1A	431970	425956	single nucleotide variant	31-Oct-18	2	chr12	120996568	C	G	10/31/18	49959	1	14	14	FALSE	TRUE	Likely pathogenic	chr12:120996568:C:G	NA	NA	NA	NA	VUS	"Reassessed because of high AC, Adding BA1 changed variant to VUS. Also removed PS3 evidence showing that the variant led to increased bile acid synthesis. Uncertain significance - conflicting evidence: The p.Pro379Ala variant in HNF1A has been reported in 8 individuals with maturity-onset diabetes of the young type 3 (PMID: 19754856, 29207974, 23607861, 30202817, 30155490, 2176128) and has been Identified in 0.07914% (28/35382) of Latino chromosomes, and at lower frequencies in other populations, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs754729248). This variant has also been reported in ClinVar (VariationID: 431970) as likely pathogenic by GeneDx and as pathogenic by Fulgent Genetics. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Pro379Ala have been reported in association with disease in the literature, suggesting that this variant is in a mutational hot spot and supports pathogenicity (PMID: 23348805, 16917892). Three additional likely pathogenic variants, resulting in a different amino acid change at the same position, p.Pro379Thr, p.Pro379Arg, and p.Pro379His, have been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 23348805, 16917892, 29666556, 15657605, 15883474, 30293189, 21683639, 26479152, 28012402).  In summary the clinical significance of the p.Pro379Ala variant is uncertain. ACMG/AMP Criteria applied: BA1, PS4_moderate, PM1, PM5, PP3,  (Richards 2015)."	maturity-onset diabetes of the young type 3	VUS	"Reassessed because of high AC, Adding BA1 changed variant to VUS. Also removed PS3 evidence showing that the variant led to increased bile acid synthesis. Uncertain significance - conflicting evidence: The p.Pro379Ala variant in HNF1A has been reported in 8 individuals with maturity-onset diabetes of the young type 3 (PMID: 19754856, 29207974, 23607861, 30202817, 30155490, 2176128) and has been Identified in 0.07914% (28/35382) of Latino chromosomes, and at lower frequencies in other populations, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs754729248). This variant has also been reported in ClinVar (VariationID: 431970) as likely pathogenic by GeneDx and as pathogenic by Fulgent Genetics. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Pro379Ala have been reported in association with disease in the literature, suggesting that this variant is in a mutational hot spot and supports pathogenicity (PMID: 23348805, 16917892). Three additional likely pathogenic variants, resulting in a different amino acid change at the same position, p.Pro379Thr, p.Pro379Arg, and p.Pro379His, have been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 23348805, 16917892, 29666556, 15657605, 15883474, 30293189, 21683639, 26479152, 28012402).  In summary the clinical significance of the p.Pro379Ala variant is uncertain. ACMG/AMP Criteria applied: BA1, PS4_moderate, PM1, PM5, PP3,  (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr20-44413714-C-T	20-43042354-C-T	HNF4A	9212	24251	single nucleotide variant	12-Dec-17	3	chr20	44413714	C	T	12/12/17	49960	0	22	22	FALSE	FALSE	NA	chr20:44413714:C:T	VUS	"Uncertain Significance - Conflicting Evidence: BS2, PP3; also VUS by high confidence lab (GeneDx)"	NA	NA	NA	NA	NA	VUS	Uncertain Significance - Conflicting Evidence	"MODY, MODY Extended, MonogenicDM_all"chr20-44413735-A-G	20-43042375-A-G	HNF4A	36349	45013	single nucleotide variant	20-Mar-17	2	chr20	44413735	A	G	3/20/17	49960	0	24	24	TRUE	FALSE	NA	chr20:44413735:A:G	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Ser143Gly variant in HNF4A has been reported in 1 individual with Maturity-Onset Diabetes of the Young in ClinVar (Variation ID: 36349), and has been identified in 0.01145% (13/113552) of European (non-Finnish) chromosomes and 0.002894% (1/34554) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922472). This variant has also been reported in an individual without diabetes (PMID: 24097065). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 36349). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Ser143Gly variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015)."	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Ser143Gly variant in HNF4A has been reported in 1 individual with Maturity-Onset Diabetes of the Young in ClinVar (Variation ID: 36349), and has been identified in 0.01145% (13/113552) of European (non-Finnish) chromosomes and 0.002894% (1/34554) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922472). This variant has also been reported in an individual without diabetes (PMID: 24097065). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 36349). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Ser143Gly variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr20-44419818-G-C	20-43048458-G-C	HNF4A	36360	45024	single nucleotide variant	18-Aug-11	1	chr20	44419818	G	C	8/18/11	49960	0	6	6	FALSE	FALSE	NA	chr20:44419818:G:C	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Glu278Asp variant in HNF4A has been reported in one individual with suspected Maturity-Onset Diabetes of the Young (PMID: 26059258), and has been identified in 0.004005% (1/24968) of African chromosomes and 0.0007741% (1/129180) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922477). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and likely benign in the literature (Variation ID: 36360; PMID: 26059258). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.Glu278Asp variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting (Richards 2015)."	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.Glu278Asp variant in HNF4A has been reported in one individual with suspected Maturity-Onset Diabetes of the Young (PMID: 26059258), and has been identified in 0.004005% (1/24968) of African chromosomes and 0.0007741% (1/129180) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922477). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and likely benign in the literature (Variation ID: 36360; PMID: 26059258). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.Glu278Asp variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr20-44424123-G-A	20-43052763-G-A	HNF4A	586023	577863	single nucleotide variant	22-Nov-17	2	chr20	44424123	G	A	11/22/17	49960	0	1	1	FALSE	FALSE	NA	chr20:44424123:G:A	NA	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: Variant has BS1 frequency 0.005% but only 1 het on gnomad--south asian population. If PM2 it is LP, if not it is VUS. The p.Arg333His variant in HNF4A has been reported in at least 3 individuals with maturity-onset diabetes of the young type 1 (MODY1) (PMID: 24947580, 25414397, 26059258) and has been Identified in 0.005451% (1/18346) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs1375557127). In vitro functional studies demonstrating reduced relative activity in cells transfected with the variant provide some evidence that the p.Arg333His variant may slightly impact protein function (PMID: 23485969). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The p.Arg333His variant is located in a region of HNF1A that is essential to ligand binding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 23485969). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: BS1, PM2, PP3, PS4_supporting, PS3_supporting, PM1_supporting (Richards 2015)."	maturity-onset diabetes of the young type 1	VUS	"Uncertain significance - insufficient evidence: Variant has BS1 frequency 0.005% but only 1 het on gnomad--south asian population. If PM2 it is LP, if not it is VUS. The p.Arg333His variant in HNF4A has been reported in at least 3 individuals with maturity-onset diabetes of the young type 1 (MODY1) (PMID: 24947580, 25414397, 26059258) and has been Identified in 0.005451% (1/18346) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs1375557127). In vitro functional studies demonstrating reduced relative activity in cells transfected with the variant provide some evidence that the p.Arg333His variant may slightly impact protein function (PMID: 23485969). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The p.Arg333His variant is located in a region of HNF1A that is essential to ligand binding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 23485969). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: BS1, PM2, PP3, PS4_supporting, PS3_supporting, PM1_supporting (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr13-27924574-C-T	13-28498711-C-T	PDX1	36411	45074	single nucleotide variant	28-Mar-16	2	chr13	27924574	C	T	3/28/16	49960	0	165	165	FALSE	FALSE	NA	chr13:27924574:C:T	NA	NA	NA	NA	Benign	"The p.Pro242Leu variant in PDX1 has been reported in at least 1 Asian individual with maturity-onset diabetes of the young type 4 (PMID: 27420379), and has been identified in 0.2% (124/58140) of European (non-Finnish) chromosomes and multiple other populations at lower frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922358). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 36411). Computational prediction tools, including splice predictors, and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, this variant meets criteria to be classified as benign for MODY type 4 in an autosomal dominant manner based on computational tool predictions and the frequency of this variant in multiple populations. ACMG/AMP Criteria applied: BP4, BA1 (Richards 2015)."	MODY type IV	Benign	"The p.Pro242Leu variant in PDX1 has been reported in at least 1 Asian individual with maturity-onset diabetes of the young type 4 (PMID: 27420379), and has been identified in 0.2% (124/58140) of European (non-Finnish) chromosomes and multiple other populations at lower frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922358). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 36411). Computational prediction tools, including splice predictors, and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, this variant meets criteria to be classified as benign for MODY type 4 in an autosomal dominant manner based on computational tool predictions and the frequency of this variant in multiple populations. ACMG/AMP Criteria applied: BP4, BA1 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr13-27920364-G-A	13-28494501-G-A	PDX1	8859	23898	single nucleotide variant	5-Feb-18	6	chr13	27920364	G	A	2/5/18	49960	0	584	582	TRUE	FALSE	NA	chr13:27920364:G:A	NA	NA	Benign	"The p.Asp76Asn variant in PDX1 (sometimes called IPF1) has been reported in at least 32 individuals with Maturity-Onset Diabetes of the Young (PMID: 15277425, 10545531, 10545530, 17592437), and has been identified in 0.4909% (336/68440) of European (non-Finnish) chromosomes, including 2 homozygotes, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852783). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. However, this variant does not segregate with disease in many families, including sibling pairs (PMID: 10545531, 15277425). This variant has also been reported as a benign variant, likely benign variant, VUS, likely pathogenic variant, and risk factor for diabetes in ClinVar (Variation ID: 8859). In vitro functional studies provide some evidence that the p.Asp76Asn variant may slightly impact protein function, but this evidence is not conclusive (PMID: 10545531). These types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, this variant meets criteria to be classified as benign for Maturity-Onset Diabetes of the Young in an autosomal dominant manner based on a higher than expected frequency in control cohorts and nonsegregation with MODY. ACMG/AMP Criteria applied: BS2, BS4, BP4 (Richards 2015)."	NA	NA	NA	Benign	"The p.Asp76Asn variant in PDX1 (sometimes called IPF1) has been reported in at least 32 individuals with Maturity-Onset Diabetes of the Young (PMID: 15277425, 10545531, 10545530, 17592437), and has been identified in 0.4909% (336/68440) of European (non-Finnish) chromosomes, including 2 homozygotes, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852783). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. However, this variant does not segregate with disease in many families, including sibling pairs (PMID: 10545531, 15277425). This variant has also been reported as a benign variant, likely benign variant, VUS, likely pathogenic variant, and risk factor for diabetes in ClinVar (Variation ID: 8859). In vitro functional studies provide some evidence that the p.Asp76Asn variant may slightly impact protein function, but this evidence is not conclusive (PMID: 10545531). These types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, this variant meets criteria to be classified as benign for Maturity-Onset Diabetes of the Young in an autosomal dominant manner based on a higher than expected frequency in control cohorts and nonsegregation with MODY. ACMG/AMP Criteria applied: BS2, BS4, BP4 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr13-27920320-GC-G	13-28494457-GC-G	PDX1	21124	33976	deletion	25-Jan-17	3	chr13	27920320	GC	G	1/25/17	49958	2	1	1	FALSE	FALSE	NA	chr13:27920320:GC:G	NA	NA	NA	NA	Pathogenic	"The p.Pro63Argfs variant in PDX1 has been reported in 9 individuals with maturity-onset diabetes of the young type 4 (MODY type 4), segregated with disease in those 9 affected relatives from 1 family (PMID: 20621032), and this variant has been identified in 0.002% (1/49632) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; rs193929377). This variant has also been reported in ClinVar as pathogenic (Variation ID: 21124). In vitro functional studies provide some evidence that the p.Pro63Argfs variant may slightly impact protein function (PMID:15001545). However, these types of assays may not accurately represent biological function. This variant is predicted to cause a frameshift, which alters the proteins amino acid sequence beginning at position 63 and leads to a premature termination codon 60 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the PDX1 gene is an established disease mechanism in MODY type 4. In summary, this variant meets criteria to be classified as pathogenic for MODY type 4 in an autosomal dominant manner based on the predicted impact of this loss of function variant and the strong segregation seen with this variant and MODY type 4. ACMG/AMP Criteria applied: PVS1, PP1_strong, PM2, PS3_supporting (Richards 2015)."	MODY type IV	Pathogenic	"The p.Pro63Argfs variant in PDX1 has been reported in 9 individuals with maturity-onset diabetes of the young type 4 (MODY type 4), segregated with disease in those 9 affected relatives from 1 family (PMID: 20621032), and this variant has been identified in 0.002% (1/49632) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; rs193929377). This variant has also been reported in ClinVar as pathogenic (Variation ID: 21124). In vitro functional studies provide some evidence that the p.Pro63Argfs variant may slightly impact protein function (PMID:15001545). However, these types of assays may not accurately represent biological function. This variant is predicted to cause a frameshift, which alters the proteins amino acid sequence beginning at position 63 and leads to a premature termination codon 60 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the PDX1 gene is an established disease mechanism in MODY type 4. In summary, this variant meets criteria to be classified as pathogenic for MODY type 4 in an autosomal dominant manner based on the predicted impact of this loss of function variant and the strong segregation seen with this variant and MODY type 4. ACMG/AMP Criteria applied: PVS1, PP1_strong, PM2, PS3_supporting (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr13-27920190-T-C	13-28494327-T-C	PDX1	8862	23901	single nucleotide variant	10-Oct-16	2	chr13	27920190	T	C	10/10/16	49960	0	27	27	FALSE	FALSE	NA	chr13:27920190:T:C	NA	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence:  Variant seems to be somewhat damaging but with very low penetrance, also, maybe use BS1? Seems mostly associated with T2D than MODY. The p.Cys18Arg variant in PDX1 has been reported in at least 3 individuals with type 2 diabetes mellitus (PMID: 10545530, 27879214; DOI: 10.7324/JABB.2013.1205), and has been identified in 0.02173% (15/69030) of European (non-Finnish) chromosomes, 0.01066% (2/18762) of European (Finnish) chromosomes, and 0.003943% (1/25360) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852785). In vitro functional studies provide some evidence that the p.Cys18Arg variant may slightly impact protein function, resulting in moderately decreased binding activity to the insulin promoter and decreased transcription of insulin in response to hyperglycemia  (PMID: 30930126, 10545530). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The p.Cys18Arg variant did not segregate with type 2 diabetes mellitus in 3 affected relatives of  individuals with the variant, suggesting that this variant is not pathogenic for type 2 diabetes mellitus (PMID: 10545530). The variant is located in a region of PDX1 that is important for protein binding, suggesting that this variant is in a functional domain and slighly supports pathogenicity (PMID: 27879214).  In summary, the clinical significance of the p.Cys18Arg variant is uncertain. ACMG/AMP Criteria applied: BS4, PP3, PS4_supporting, PS3_supporting, PM1_supporting (Richards 2015)."	type 2 diabetes mellitus	VUS	"Uncertain significance - insufficient evidence:  Variant seems to be somewhat damaging but with very low penetrance, also, maybe use BS1? Seems mostly associated with T2D than MODY. The p.Cys18Arg variant in PDX1 has been reported in at least 3 individuals with type 2 diabetes mellitus (PMID: 10545530, 27879214; DOI: 10.7324/JABB.2013.1205), and has been identified in 0.02173% (15/69030) of European (non-Finnish) chromosomes, 0.01066% (2/18762) of European (Finnish) chromosomes, and 0.003943% (1/25360) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852785). In vitro functional studies provide some evidence that the p.Cys18Arg variant may slightly impact protein function, resulting in moderately decreased binding activity to the insulin promoter and decreased transcription of insulin in response to hyperglycemia  (PMID: 30930126, 10545530). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The p.Cys18Arg variant did not segregate with type 2 diabetes mellitus in 3 affected relatives of  individuals with the variant, suggesting that this variant is not pathogenic for type 2 diabetes mellitus (PMID: 10545530). The variant is located in a region of PDX1 that is important for protein binding, suggesting that this variant is in a functional domain and slighly supports pathogenicity (PMID: 27879214).  In summary, the clinical significance of the p.Cys18Arg variant is uncertain. ACMG/AMP Criteria applied: BS4, PP3, PS4_supporting, PS3_supporting, PM1_supporting (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr13-27920235-C-A	13-28494372-C-A	PDX1	36414	45077	single nucleotide variant	10-Jun-16	2	chr13	27920235	C	A	6/10/16	49947	13	189	187	FALSE	FALSE	NA	chr13:27920235:C:A	NA	NA	NA	NA	VUS	"Uncertain significance - conflicting evidence: The p.Pro33Thr variant in PDX1 has been reported in 1 individual with maturity-onset diabetes of the young type 4 (PMID: 16092045), but has been identified in 0.7% (164/22330) of South Asian chromosomes as well as other populations at lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs192902098). This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 36414). In vitro functional studies provide some evidence that the p.Pro33Thr variant may impact protein function (PMID: 16092045, 30930126). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. ACMG/AMP Criteria applied: BA1, PS3_moderate, PP3 (Richards 2015)."	MODY type IV	VUS	"Uncertain significance - conflicting evidence: The p.Pro33Thr variant in PDX1 has been reported in 1 individual with maturity-onset diabetes of the young type 4 (PMID: 16092045), but has been identified in 0.7% (164/22330) of South Asian chromosomes as well as other populations at lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs192902098). This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 36414). In vitro functional studies provide some evidence that the p.Pro33Thr variant may impact protein function (PMID: 16092045, 30930126). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. ACMG/AMP Criteria applied: BA1, PS3_moderate, PP3 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all"chr17-37731634-G-A	17-36091625-G-A	HNF1B	36837	45498	single nucleotide variant	18-Aug-11	1	chr17	37731634	G	A	8/18/11	49950	10	5	5	FALSE	FALSE	NA	chr17:37731634:G:A	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.His336Tyr variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 377055), and has been identified in 0.02611% (9/34468) of Latino chromosomes and 0.0008848% (1/113020) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs138986885). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36837). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.His336Tyr variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015)."	NA	NA	NA	VUS	"Uncertain significance - insufficient evidence: The p.His336Tyr variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 377055), and has been identified in 0.02611% (9/34468) of Latino chromosomes and 0.0008848% (1/113020) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs138986885). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36837). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.His336Tyr variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015)."	"MODY, MODY Extended, MonogenicDM_all, Neonatal Diabetes"chr17-37710601-C-T	17-36070609-C-T	HNF1B	379811	376001	single nucleotide variant	5-Jul-18	2	chr17	37710601	C	T	7/5/18	49960	0	5	5	FALSE	TRUE	Uncertain significance	chr17:37710601:C:T	VUS	"Uncertain Significance - Insufficient Evidence: PP1, PM2; also VUS by high confidence lab (GeneDx and EGL) after Jan 2017"	NA	NA	NA	NA	NA	VUS	Used HC lab assessment	"MODY, MODY Extended, MonogenicDM_all, Neonatal Diabetes"chr18-60371513-G-GCA	18-58038746-G-GCA	MC4R	36487	45149	duplication	18-Aug-11	1	chr18	60371513	G	GCA	8/18/11	49958	2	3	3	FALSE	FALSE	NA	chr18:60371513:G:GCA	NA	NA	NA	NA	Likely Pathogenic	NA	obesity	Likely Pathogenic	NA	Obesitychr18-60371598-ATC-A	18-58038831-ATC-A	MC4R	435828	430075	deletion	29-Jul-16	2	chr18	60371598	ATC	A	7/29/16	48633	1327	2	2	FALSE	FALSE	NA	chr18:60371598:ATC:A	NA	NA	NA	NA	Likely Pathogenic	NA	obesity	Likely Pathogenic	NA	Obesitychr18-60371856-C-T	18-58039089-C-T	MC4R	327713	347739	single nucleotide variant	14-Jun-16	1	chr18	60371856	C	T	6/14/16	49960	0	4	4	FALSE	FALSE	NA	chr18:60371856:C:T	NA	NA	Likely Pathogenic	NA	NA	NA	NA	Likely Pathogenic	NA	Obesitychr18-60371601-A-T	18-58038834-A-T	MC4R	549551	540034	single nucleotide variant	10-Mar-17	2	chr18	60371601	A	T	3/10/17	49960	0	1	1	FALSE	FALSE	NA	chr18:60371601:A:T	NA	NA	Likely Pathogenic	NA	NA	NA	NA	Likely Pathogenic	NA	Obesitychr18-60371970-G-A	18-58039203-G-A	MC4R	14336	29375	single nucleotide variant	25-May-17	6	chr18	60371970	G	A	5/25/17	49960	0	6	6	TRUE	FALSE	NA	chr18:60371970:G:A	VUS	Conflicting evidence	Pathogenic	NA	Likely Pathogenic	NA	NA	Likely Pathogenic	Conflicting evidence	Obesitychr18-60372169-C-T	18-58039402-C-T	MC4R	435831	430078	single nucleotide variant	30-Aug-16	3	chr18	60372169	C	T	8/30/16	49960	0	4	4	FALSE	FALSE	NA	chr18:60372169:C:T	Pathogenic	"PM2 (Absent in population databases) upgraded in strength to Strong, PS4 (Prevalence in affecteds statistically increased over controls) upgraded in strength to Very Strong"	NA	NA	Likely Pathogenic	NA	NA	Likely Pathogenic	"PM2 (Absent in population databases) upgraded in strength to Strong, PS4 (Prevalence in affecteds statistically increased over controls) upgraded in strength to Very Strong"	Obesitychr18-60371538-C-T	18-58038771-C-T	MC4R	14329	29368	single nucleotide variant	10-Dec-15	3	chr18	60371538	C	T	12/10/15	49960	0	5	5	FALSE	FALSE	NA	chr18:60371538:C:T	NA	NA	NA	NA	Pathogenic	NA	obesity	Pathogenic	NA	Obesitychr18-60371827-C-T	18-58039060-C-T	MC4R	14330	29369	single nucleotide variant	16-Mar-11	2	chr18	60371827	C	T	3/16/11	49960	0	17	17	FALSE	FALSE	NA	chr18:60371827:C:T	VUS	Conflicting evidence	NA	NA	NA	NA	NA	VUS	Conflicting evidence	Obesitychr18-60371454-G-T	18-58038687-G-T	MC4R	36488	45150	single nucleotide variant	18-Aug-11	1	chr18	60371454	G	T	8/18/11	49960	0	1	1	FALSE	FALSE	NA	chr18:60371454:G:T	VUS	Conflicting evidence	NA	NA	NA	NA	NA	VUS	Conflicting evidence	Obesitychr18-60371593-C-T	18-58038826-C-T	MC4R	492862	485791	single nucleotide variant	4-Mar-14	1	chr18	60371593	C	T	3/4/14	49960	0	9	9	FALSE	FALSE	NA	chr18:60371593:C:T	NA	NA	VUS	NA	NA	NA	NA	VUS	NA	Obesitychr18-60372285-CTG-C	18-58039518-CTG-C	MC4R	492860	485793	deletion	8-Sep-16	1	chr18	60372285	CTG	C	9/8/16	49960	0	1	1	FALSE	FALSE	NA	chr18:60372285:CTG:C	NA	NA	NA	NA	VUS	NA	obesity	VUS	NA	Obesitychr18-60372245-G-T	18-58039478-G-T	MC4R	14318	29357	single nucleotide variant	14-Aug-18	8	chr18	60372245	G	T	8/14/18	49960	0	4	4	FALSE	TRUE	Pathogenic	chr18:60372245:G:T	NA	NA	Pathogenic	NA	NA	NA	NA	Pathogenic	NA	Obesity